**Guideline Page and Request**  
**Panel Discussion**  
**Vote**  
**References**

| **KID-4** | **Internal requests:**  
Panel discussion comment regarding systemic therapy for non-clear cell histology:  
Re-evaluate the category 3 status for  
- Pazopanib  
- Erlotinib  
- Axitinib  
Panel discussion comment to add bevacizumab as a systemic therapy option for non-clear cell histology.  
Panel discussion comment to add everolimus as a systemic therapy option for non-clear cell histology. | **External request:**  
Submission from Novartis Oncology to consider the addition of everolimus for the treatment of non-clear cell renal cell carcinoma. | **The panel discussion and vote regarding systemic therapy for non-clear cell histology resulted in a consensus to make the following category changes:**  
- Pazopanib was changed from a category 3 to a category 2A.  
- Erlotinib was changed from a category 3 to a category 2A.  
- Axitinib was changed from a category 3 to a category 2A.  
**The panel consensus was to add bevacizumab as a systemic therapy option for non-clear cell histology.**  
**Based on the noted references and panel discussion, the consensus was to add everolimus as a systemic therapy option for non-clear cell histology as a category 2A.** | **YES** | **NO** | **ABSTAIN** | **Irshad T, Olencki T, Zynger DL, et al. Bevacizumab in metastatic papillary renal cell carcinoma (PRCC). ASCO Meeting Abstracts 2011;29:e15158. Available at: http://meeting.ascopubs.org/cgi/content/abstract/29/15_suppl/e15158.**  